Literature DB >> 30082822

AKT activation is a feature of CALR mutant myeloproliferative neoplasms.

Chunling Fu1,2, Qiang Jeremy Wen2, Christian Marinaccio2, Te Ling2, Wei Chen1,2, Marinka Bulic2, Terra Lasho3, Ayalew Tefferi3, John D Crispino4, Kailin Xu5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30082822      PMCID： PMC6328327          DOI： 10.1038/s41375-018-0224-8

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  9 in total

1.  Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.

Authors:  Shannon Elf; Nouran S Abdelfattah; Edwin Chen; Javier Perales-Patón; Emily A Rosen; Amy Ko; Fabian Peisker; Natalie Florescu; Silvia Giannini; Ofir Wolach; Elizabeth A Morgan; Zuzana Tothova; Julie-Aurore Losman; Rebekka K Schneider; Fatima Al-Shahrour; Ann Mullally
Journal:  Cancer Discov       Date:  2016-03-07       Impact factor: 39.397

2.  Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.

Authors:  Caroline Marty; Christian Pecquet; Harini Nivarthi; Mira El-Khoury; Ilyas Chachoua; Micheline Tulliez; Jean-Luc Villeval; Hana Raslova; Robert Kralovics; Stefan N Constantinescu; Isabelle Plo; William Vainchenker
Journal:  Blood       Date:  2015-11-25       Impact factor: 22.113

Review 3.  The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.

Authors:  Gabriela S Hobbs; Sarah Rozelle; Ann Mullally
Journal:  Hematol Oncol Clin North Am       Date:  2017-05-17       Impact factor: 3.722

4.  Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.

Authors:  Ilyas Chachoua; Christian Pecquet; Mira El-Khoury; Harini Nivarthi; Roxana-Irina Albu; Caroline Marty; Vitalina Gryshkova; Jean-Philippe Defour; Gaëlle Vertenoeil; Anna Ngo; Ann Koay; Hana Raslova; Pierre J Courtoy; Meng Ling Choong; Isabelle Plo; William Vainchenker; Robert Kralovics; Stefan N Constantinescu
Journal:  Blood       Date:  2015-12-14       Impact factor: 22.113

Review 5.  Definition and management of ruxolitinib treatment failure in myelofibrosis.

Authors:  A Pardanani; A Tefferi
Journal:  Blood Cancer J       Date:  2014-12-12       Impact factor: 11.037

6.  AKT is a therapeutic target in myeloproliferative neoplasms.

Authors:  I Khan; Z Huang; Q Wen; M J Stankiewicz; L Gilles; B Goldenson; R Schultz; L Diebold; S Gurbuxani; C M Finke; T L Lasho; P Koppikar; A Pardanani; B Stein; J K Altman; R L Levine; A Tefferi; J D Crispino
Journal:  Leukemia       Date:  2013-06-10       Impact factor: 11.528

7.  Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion.

Authors:  Lijuan Han; Claudia Schubert; Johanna Köhler; Mirle Schemionek; Susanne Isfort; Tim H Brümmendorf; Steffen Koschmieder; Nicolas Chatain
Journal:  J Hematol Oncol       Date:  2016-05-13       Impact factor: 17.388

8.  Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib.

Authors:  K Shide; T Kameda; T Yamaji; M Sekine; N Inada; A Kamiunten; K Akizuki; K Nakamura; T Hidaka; Y Kubuki; H Shimoda; A Kitanaka; A Honda; A Sawaguchi; H Abe; T Miike; H Iwakiri; Y Tahara; M Sueta; S Hasuike; S Yamamoto; K Nagata; K Shimoda
Journal:  Leukemia       Date:  2016-11-03       Impact factor: 11.528

9.  A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation.

Authors:  K Kollmann; W Warsch; C Gonzalez-Arias; F L Nice; E Avezov; J Milburn; J Li; D Dimitropoulou; S Biddie; M Wang; E Poynton; M Colzani; M R Tijssen; S Anand; U McDermott; B Huntly; T Green
Journal:  Leukemia       Date:  2016-10-14       Impact factor: 11.528
  9 in total
  2 in total

1.  Cancer Biology of the Endoplasmic Reticulum Lectin Chaperones Calreticulin, Calnexin and PDIA3/ERp57.

Authors:  Shing Tat Theodore Lam; Chinten James Lim
Journal:  Prog Mol Subcell Biol       Date:  2021

2.  Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs.

Authors:  Manjola Balliu; Laura Calabresi; Niccolò Bartalucci; Simone Romagnoli; Laura Maggi; Rossella Manfredini; Matteo Lulli; Paola Guglielmelli; Alessandro Maria Vannucchi
Journal:  Blood Adv       Date:  2021-04-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.